Fortis Healthcare Ltd
Fortis Healthcare Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Hospital business expects medium-term revenue growth of around 14%-15% year-on-year, driven by ~5%-6% ARPOB growth and bed expansion alongside better utilization of existing capacity (Page 11). Fortis Healthcare targets EBITDA margin expansion from the current ~20.5% to 25% in the near future.
From Fortis Healthcare Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Hospital business expects medium-term revenue growth of around 14%-15% year-on-year, driven by ~5%-6% ARPOB growth and bed expansion alongside better utilization of existing capacity (Page 11).
- Brownfield bed expansion planned at around 350-400 beds per year over the next couple of years, with enough opportunities to add 1,000+ beds beyond FY'26 on a brownfield basis (Page 12).
- Diagnostic business anticipates achieving industry-level growth of 8%-10% by Q2-Q3 of next fiscal year, driven largely by volume growth rather than price increases (Page 12).
- Specialty services like Oncology, Neurosciences, and robotic surgeries are key contributors to strong ARPOB and volume growth (Page 4 and 7).
2 more points from Fortis Healthcare Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Fortis Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capex for the year is around INR 900 crore.
- This includes approximately INR 600 crore for brownfield expansion projects.
- INR 300 crore is earmarked for maintenance capex.
- The main expansion focus is on brownfield projects; Manesar is the only greenfield project in the next 2-3 years.
- Fortis is actively evaluating acquisition opportunities and land purchases in certain high-potential areas as part of a strategic, value-driven approach.
- No specific timeline or number of acquisitions announced, as expansion is opportunistic.
2 more points from Fortis Healthcare Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fortis Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Fortis Healthcare Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Fortis Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.4K Cr, net profit ₹271 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fortis Health.'s management said in earlier quarters
Others in Healthcare Services this season
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Arthneeti Pro · Annual
Fortis Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fortis Healthcare Ltd Q3 FY25 results?
Hospital business expects medium-term revenue growth of around 14%-15% year-on-year, driven by ~5%-6% ARPOB growth and bed expansion alongside better utilization of existing capacity (Page 11). Fortis Healthcare targets EBITDA margin expansion from the current ~20.5% to 25% in the near future.
What is Fortis Healthcare Ltd share price analysis?
Fortis Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 66.1 with a market cap of ₹69,834 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fortis Healthcare Ltd planning capital expenditure?
Total capex for the year is around INR 900 crore.
Keep Fortis Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.